

Supplementary Table 1

<u>Race</u>	<u>Region</u>	<u>Country</u>	<u>Number</u>	<u>% of total</u>
<u>White /Caucasian</u>	<u>Australia /New Zealand</u>	<u>Australian</u>	<u>81</u>	<u>12.6%</u>
		<u>New Zealander</u>	<u>13</u>	<u>2.0%</u>
	<u>Europe</u>	<u>Austrian</u>	<u>19</u>	<u>3.0%</u>
		<u>Bosnian</u>	<u>3</u>	<u>0.5%</u>
		<u>British, no further designation</u>	<u>15</u>	<u>2.3%</u>
		<u>Czech</u>	<u>16</u>	<u>2.5%</u>
		<u>Dutch</u>	<u>1</u>	<u>0.2%</u>
		<u>English</u>	<u>20</u>	<u>3.1%</u>
		<u>Estonian</u>	<u>1</u>	<u>0.2%</u>
		<u>German</u>	<u>60</u>	<u>9.3%</u>
		<u>Hungarian</u>	<u>6</u>	<u>0.9%</u>
		<u>Italian</u>	<u>3</u>	<u>0.5%</u>
		<u>Latvian</u>	<u>2</u>	<u>0.3%</u>
		<u>Lithuanian</u>	<u>4</u>	<u>0.6%</u>
		<u>Maltese</u>	<u>1</u>	<u>0.2%</u>
		<u>Polish</u>	<u>100</u>	<u>15.5%</u>
		<u>Portuguese</u>	<u>6</u>	<u>0.9%</u>
		<u>Romanian</u>	<u>2</u>	<u>0.3%</u>
		<u>Russian</u>	<u>1</u>	<u>0.2%</u>
		<u>Scottish</u>	<u>4</u>	<u>0.6%</u>
		<u>Serbian</u>	<u>4</u>	<u>0.6%</u>
		<u>Slovene</u>	<u>14</u>	<u>2.2%</u>
		<u>Spanish</u>	<u>31</u>	<u>4.8%</u>
		<u>Swedish</u>	<u>5</u>	<u>0.8%</u>
	<u>North America</u>	<u>American Caucasian</u>	<u>168</u>	<u>26.1%</u>
		<u>Canadian</u>	<u>25</u>	<u>3.9%</u>
	<u>Other</u>	<u>South African</u>	<u>1</u>	<u>0.2%</u>
<u>Not Caucasian</u>	<u>East Asian</u>	<u>Filipino</u>	<u>36</u>	<u>5.6%</u>
		<u>Chinese</u>	<u>2</u>	<u>0.3%</u>

Supplementary Table 2

HLA-DQA1 and DQB1 Nomenclature based on second exon polymorphism only

<u>Designation</u>	<u>Allele Group</u>
<u>DQA1*0101g</u>	<u>DQA1*0101, *0104, *0105</u>
<u>DQA1*0301g</u>	<u>DQA1*0301, *0302, *0303</u>
<u>DQA1*0401g</u>	<u>DQA1*0401, *0402, *0403</u>
<u>DQA1*0501g</u>	<u>DQA1*0501, *0503, *0505</u>
<u>DQB1*0301g</u>	<u>DQB1*0301, *0309</u>
<u>DRB1*0602g</u>	<u>DQB1*0602, *06011</u>
<u>DQB1*0603g</u>	<u>DQB1*0603, *0614</u>

Supplementary Table 3 HLA-DR-DQ Diplotype Risk

<u>DRB1</u>	<u>DQB1</u>	<u>DRB1</u>	<u>DQB1</u>	<u>Controls</u>		<u>T1D</u>		<u>Odds Ratio</u>	<u>95%</u>	<u>C.I:</u>
				<u>n*</u>	<u>%</u>	<u>N</u>	<u>%</u>			
<u>0301</u>	<u>0201</u>	<u>0405</u>	<u>0302</u>	<u>0.3</u>	<u>0.06%</u>	<u>16</u>	<u>2.64%</u>	<u>49.22</u>	<u>0.95</u>	<u>2551.55</u>
<u>0401</u>	<u>0302</u>	<u>0401</u>	<u>0302</u>	<u>0.7</u>	<u>0.15%</u>	<u>35</u>	<u>5.78%</u>	<u>41.37</u>	<u>3.70</u>	<u>463.01</u>
<u>0301</u>	<u>0201</u>	<u>0401</u>	<u>0302</u>	<u>4.4</u>	<u>0.96%</u>	<u>157</u>	<u>25.91%</u>	<u>35.94</u>	<u>13.79</u>	<u>93.67</u>
<u>0301</u>	<u>0201</u>	<u>0402</u>	<u>0302</u>	<u>1.1</u>	<u>0.25%</u>	<u>29</u>	<u>4.79%</u>	<u>20.23</u>	<u>3.07</u>	<u>133.32</u>
<u>0801</u>	<u>0402</u>	<u>0401</u>	<u>0302</u>	<u>0.8</u>	<u>0.18%</u>	<u>14</u>	<u>2.31%</u>	<u>13.30</u>	<u>1.41</u>	<u>125.70</u>
<u>0301</u>	<u>0201</u>	<u>0404</u>	<u>0302</u>	<u>3.8</u>	<u>0.83%</u>	<u>37</u>	<u>6.11%</u>	<u>7.81</u>	<u>2.68</u>	<u>22.72</u>
<u>0101</u>	<u>0501</u>	<u>0401</u>	<u>0302</u>	<u>3.1</u>	<u>0.68%</u>	<u>28</u>	<u>4.62%</u>	<u>7.03</u>	<u>2.17</u>	<u>22.80</u>
<u>0401</u>	<u>0302</u>	<u>1302</u>	<u>0604</u>	<u>1.0</u>	<u>0.21%</u>	<u>8</u>	<u>1.32%</u>	<u>6.32</u>	<u>0.76</u>	<u>52.58</u>
<u>0401</u>	<u>0302</u>	<u>0404</u>	<u>0302</u>	<u>1.2</u>	<u>0.25%</u>	<u>9</u>	<u>1.49%</u>	<u>5.93</u>	<u>0.85</u>	<u>41.34</u>
<u>0901</u>	<u>0303</u>	<u>0401</u>	<u>0302</u>	<u>0.5</u>	<u>0.12%</u>	<u>4</u>	<u>0.66%</u>	<u>5.61</u>	<u>0.33</u>	<u>96.73</u>
<u>0301</u>	<u>0201</u>	<u>0301</u>	<u>0201</u>	<u>7.1</u>	<u>1.57%</u>	<u>46</u>	<u>7.59%</u>	<u>5.15</u>	<u>2.32</u>	<u>11.44</u>
<u>0101</u>	<u>0501</u>	<u>0402</u>	<u>0302</u>	<u>0.8</u>	<u>0.18%</u>	<u>4</u>	<u>0.66%</u>	<u>3.77</u>	<u>0.34</u>	<u>41.62</u>
<u>0801</u>	<u>0402</u>	<u>0404</u>	<u>0302</u>	<u>0.7</u>	<u>0.15%</u>	<u>2</u>	<u>0.33%</u>	<u>2.17</u>	<u>0.14</u>	<u>33.51</u>
<u>0301</u>	<u>0201</u>	<u>0901</u>	<u>0303</u>	<u>1.8</u>	<u>0.39%</u>	<u>4</u>	<u>0.66%</u>	<u>1.72</u>	<u>0.29</u>	<u>10.17</u>
<u>0301</u>	<u>0201</u>	<u>1302</u>	<u>0604</u>	<u>3.1</u>	<u>0.69%</u>	<u>6</u>	<u>0.99%</u>	<u>1.44</u>	<u>0.37</u>	<u>5.69</u>
<u>0101</u>	<u>0501</u>	<u>0404</u>	<u>0302</u>	<u>2.7</u>	<u>0.59%</u>	<u>2</u>	<u>0.33%</u>	<u>0.56</u>	<u>0.09</u>	<u>3.52</u>

*n=455 genotypes (estimated from 910 AFBAC haplotypes).

T1D= probands N=606

Selected DR-DQ diplotype risk was estimated for the high risk DR3 and DR4 haplotypes as well as the four DR-DQ haplotypes with ORs > 1.0 in Table 4. ORs have been estimated by comparing the observed frequency of diplotypes among probands with the estimated frequency of control diplotypes, based on observed frequency of AFBAC haplotypes and the assumption of Hardy-Weinberg equilibrium.

